Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

PATCH trial: explanatory analyses

M. Irem Baharoglu, Rustam Al-Shahi Salman, Charlotte Cordonnier, Maria M. Koopman, Lynn Manson, Sophie Susen, Henk A. Marquering, Ludo F. Beenen, Charles B. Majoie, Yvo B. Roos

Blood (2020) 135 (16): 1406–1409.

https://doi.org/10.1182/blood.2019003298

Published: 2020

Includes: Supplemental data

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

The Effect of Continuous Screening of Carbapenem-Resistant Enterobacteriaceae on Theprevention and Control of Bloodstream Infections in Patients with Hematopoietic Stemcell Transplantation

Tingting Yang, Xueping Luo, MD, Qing Yang, MD, Hongchao Chen, Yi Luo, MD, Yanmin Zhao, MD, Xiaoyu Lai, MD, Jian Yu, MD, Yamin Tan, MD, Guoqing Wei, MD, He Huang, Jimin Shi, MD

Blood (2019) 134 (Supplement_1): 5606.

https://doi.org/10.1182/blood-2019-127599

Published: 2019

Journal Articles

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Eduardo Huarte, PhD, Melissa Parker, Ashish Juvekar, Julian Oliver, Wenqing Yao, Paul Smith

Blood (2019) 134 (Supplement_1): 5608.

https://doi.org/10.1182/blood-2019-126749

Published: 2019

Journal Articles

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Paul F Lindholm, MD, Hau C. Kwaan, MD PhD, Andrew M Naidech, MDMSPH

Blood (2019) 134 (Supplement_1): 4886.

https://doi.org/10.1182/blood-2019-128370

Published: 2019

Journal Articles

The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis

Michelle Neier, MD, Michele P. Lambert, MD, Rachael F. Grace, MD, Kerry Hege, MD, Stephanie Chiu, MPH, Julianne Thompson, Robert J Klaassen, MD FRCPC

Blood (2019) 134 (Supplement_1): 2174.

https://doi.org/10.1182/blood-2019-125686

Published: 2019

Journal Articles

Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients

Lucky Ding, BA, Ashley E Martin, MPH, Emma Canepa, MS, Erica Evans, MD, Richard Aplenc, MD PhD, Julia E Szymczak, PhD, Galen Joseph, PhD, Lena E. Winestone, MD MSHP

Blood (2019) 134 (Supplement_1): 3415.

https://doi.org/10.1182/blood-2019-124236

Published: 2019

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Blood (2019) 134 (Supplement_1): 357.

https://doi.org/10.1182/blood-2019-131939

Published: 2019

Journal Articles

Symptom Duration Is Positively Correlated with Factor XIIIa Activity in Acute Pulmonary Embolism

Yevgeniy Brailovsky, DO, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Kevin Simpson, Nathan Mcclane, Jawed Fareed, PhD, Amir Darki, MD MSc

Blood (2018) 132 (Supplement 1): 5047.

https://doi.org/10.1182/blood-2018-99-119733

Published: 2018

Journal Articles

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Joanna Rhodes, MD, Anthony R. Mato, MD MSCE, Nicole Winchell, Kaitlin Kennard, RN, BSN, James Nathan Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2018-99-115377

Published: 2018

Journal Articles

Kaposiform Lymphangiomatosis: Update on Outcomes and Use of Sirolimus As a Therapeutic Intervention

Whitney Eng, MD, Hasan Al-Sayegh, Clement Ma, PhD, Denise Adams, MD

Blood (2018) 132 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2018-99-110989

Published: 2018

Journal Articles

Clinical Spectrum of Patients with Pathogenic Variant of STAT3 conferring Gain-of-Function: A Mimic of Autoimmune Lymphoproliferative Syndrome

Gregory Constantine, MD, Helen Su, MD, PhD, Les Folio, MD, Joshua Milner, MD, V. Koneti Rao, MD FRCPA

Blood (2018) 132 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2018-99-111950

Published: 2018

Journal Articles

Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma

Akanksha Sharma, MD BSc, Natalie Ertz-Archambault, MD, Luke Mountjoy, DO, Alyx Porter, MD, Maciej M Mrugala, MD PhD MPH

Blood (2018) 132 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2018-99-113690

Published: 2018

Journal Articles

A New Flow-Based Assay to Assess Treatment Response in Congenital Thrombotic Thrombocytopenic Purpura

Ferras Alwan, Chiara Vendramin, Alice Taylor, Mari Thomas, PhD, Ri Liesner, Marie Scully, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2018-99-115965

Published: 2018

Journal Articles

Excellence in PNH in Canada (EPIC): A Single Centre Pilot Project Evaluating Disease Trajectory for PNH Patients Receiving Eculizumab

Michael James Vernon, MD BSc, Kevin H. M. Kuo, MD MSc, FRCPC, Rebecca Leroux, BSc, Christopher J. Patriquin, MD MSc, FRCPC

Blood (2018) 132 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2018-99-112337

Published: 2018

Journal Articles

Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

Thomas Brannagan, Annabel K. Wang, Teresa Coelho, Marcia Waddington Cruz, Michael J. Polydefkis, Peter J. Dyck, Violaine Plante-Bordeneuve, John L. Berk, Fabio Barroso, Giampaolo Merlini, Isabel Conceição, Steven G. Hughes, Jesse G. Kwoh, Shiangtung W. Jung, Spencer Guthrie, Michael Pollock, Merrill D. Benson, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 498.

https://doi.org/10.1182/blood-2018-99-116995

Published: 2018

Journal Articles

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4803.

https://doi.org/10.1182/blood-2018-99-119216

Published: 2018

Journal Articles

Cytokine Release Syndrome after Peripheral Blood T-Cell Replete Haploidentical Transplantation Is Not Prevented By Dexamethasone and Limits Its Full-Outpatient Conduction

Perla R. Colunga Pedraza, MD, Andrés Gómez-De León, MD, Julia Esther Colunga Pedraza, MD, Emmanuel Bugarin Estrada, MD, Paola Santana-Hernandez, MD, Olga Cantu Rodriguez, MD, Cesar Homero Gutierrez Aguirre, MD, Luz del Carmen Tarín Arzaga, MD, José Miguel Yañez Reyes, MD, David Gomez-Almaguer, MD

Blood (2018) 132 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2018-99-116996

Published: 2018

Journal Articles

Congenital Methemoglobinemia Under Diagnosed Condition with Variiable Therapeurtic Options

Mohamed A. Yassin, MBBS,MSc,CABM,FACP,MSC, Dina Sameh Soliman, PhD

Blood (2017) 130 (Supplement 1): 4746.

https://doi.org/10.1182/blood.V130.Suppl_1.4746.4746

Published: 2017

Journal Articles

Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients

Stella Bowcock, MDMA, Catherine Atkin, MD, Gulnaz Iqbal, PhD, Tim Planche, MDPhD, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Eric Low, BSc, Helen Higgins, MSc, Janet Dunn, PhD, Mark T Drayson, MD PhD

Blood (2017) 130 (Supplement 1): 2132.

https://doi.org/10.1182/blood.V130.Suppl_1.2132.2132

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PATCH trial: explanatory analyses

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

The Effect of Continuous Screening of Carbapenem-Resistant Enterobacteriaceae on Theprevention and Control of Bloodstream Infections in Patients with Hematopoietic Stemcell Transplantation

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis

Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Symptom Duration Is Positively Correlated with Factor XIIIa Activity in Acute Pulmonary Embolism

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Kaposiform Lymphangiomatosis: Update on Outcomes and Use of Sirolimus As a Therapeutic Intervention

Clinical Spectrum of Patients with Pathogenic Variant of STAT3 conferring Gain-of-Function: A Mimic of Autoimmune Lymphoproliferative Syndrome

Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma

A New Flow-Based Assay to Assess Treatment Response in Congenital Thrombotic Thrombocytopenic Purpura

Excellence in PNH in Canada (EPIC): A Single Centre Pilot Project Evaluating Disease Trajectory for PNH Patients Receiving Eculizumab

Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Cytokine Release Syndrome after Peripheral Blood T-Cell Replete Haploidentical Transplantation Is Not Prevented By Dexamethasone and Limits Its Full-Outpatient Conduction

Congenital Methemoglobinemia Under Diagnosed Condition with Variiable Therapeurtic Options

Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only